news1

No Image

OneMedPlace Announces Program Updates for Its 6th Annual “OneMedForum,” Jan. 7-9, 2013, in San Francisco

November 29, 2012 OneMedPlace Team 0

The 6th Annual OneMedForum will take place concurrently with the JP Morgan Healthcare Conference and will feature over 1,000 attendees and more than 100 emerging growth companies from the biotech and medical device sectors. The conference draws a diverse investor attendee base, including: venture capital, private equity, angel networks, family offices, hedge funds, high-net-worth individuals, international investors, research analysts, and strategic partners.

No Image

Release: Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson’s Disease

November 28, 2012 OneMedPlace Team 0

Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

No Image

Diagnostics: Biomarkers, Gene Patents, and Personalized Medicine in Jeopardy

November 19, 2012 OneMedPlace Team 1

Fallout from the the US Supreme Court landmark decision to deny two patents to Prometheus Laboratories may complicate the future profitability of the industry. If this is indeed a precedent-setting decision, biomarker patents may now fall under the realm of “law of nature”, cutting off the prospect of exclusive market penetration that once justified the significant research and development onus in the early stages.

No Image

OneMedRadio: DARA BioSciences CEO on Oncology Market Opportunity, Key Catalysts

November 9, 2012 OneMedPlace Team 0

In Part II of our discussion with DARA Biosciences (NASDAQ: DARA) CEO and Chief Medical Officer Dr. David Drutz, we look into key catalysts for the specialty pharmaceutical company. Dr. Drutz discusses the medical need for the oral-liquid tamoxifen, Soltamox, licensed to DARA by UK-based Rosemont Pharmaceuticals — as well as the market opportunity in developing oncology services.

No Image

BIOTECH 2012: Panel of CEOs — Lather, Rinse, Repeat

October 26, 2012 Lisa Sher 0

Hosted by BioNJ, Pennsylvania Bio and Delaware Bio, their three word mission: “Find. Fund. Facilitate.” was clearly accomplished. Networking is still an integral part of these cerebral gatherings, however programming at this conference provided attendees with candid information, stimulating conversation and a new perspective on the industry.

No Image

CEVEC Pharmaceuticals GmbH Raises € 2.8MM in Series C Financing

October 26, 2012 OneMedPlace Team 0

CEVEC Pharmaceuticals GmbH (CEVEC), the developer of a novel human expression system for the manufacturing of complex biopharmaceuticals and vaccines announced today that it raised an additional amount of € 2.8 million in a Series C financing led by Peppermint VenturePartners (PVP) via the new Charité Biomedical Fund.

No Image

Release: Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson’s Disease

October 25, 2012 OneMedPlace Team 0

The following is a news release published October 25 by Amarantus BioSciences discussing positive behavioural efficacy data for MANF, the company’s powerful therapeutic protein with neuron-protective properties. Data from a neurorestoration 6-hydroxydopamine (6-OHDA) rat model Parkinson’s disease shows superiority of MANF over GDNF.

No Image

DARA Biosciences Execs Discuss Oncology Supportive Care, In-License Portfolio, and Drug Pipeline

October 23, 2012 OneMedPlace Team 0

DARA Biosciences has created some buzz as of late, landing on several ‘watch lists’ after the company’s exclusive licensing of three market-ready products for distribution in the United States. CEO/Chief Medical Officer Dr. David Drutz and COO Chris Clement conducted a two-part interview with OneMedRadio discussing developmental milestones and key catalysts for Q4-2012 and 2013.